Catalysts / PRAX
Upcoming FDA decisions and readouts we track for Praxis Precision Medicines, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Praxis Precision Medicines (PRAX, listed on Nasdaq). They cover 2 programmes: Relutrigine (SCN2A and SCN8A developmental epileptic encephalopathies) and Ulixacaltamide (Essential tremor).
First on the list: the PDUFA date (extended) for Relutrigine (SCN2A and SCN8A developmental epileptic encephalopathies), dated 27 Dec 2026. By stage, the upcoming rows are 1 PDUFA date (extended) and 1 PDUFA date.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Praxis Precision Medicines PRAX · Nasdaq | Relutrigine | SCN2A and SCN8A developmental epileptic encephalopathies | 27 Dec 2026 in 81d |
PDUFA date (extended) | Verified | 8-K press release ↗ | Yes |
| Praxis Precision Medicines PRAX · Nasdaq | Ulixacaltamide | Essential tremor | 29 Jan 2027 in 114d |
PDUFA date | Verified | 8-K press release ↗ | Yes |
FreeBioList